Karyopharm Therapeutics’ latest quarterly filing reveals that while sales of its flagship drug XPOVIO continue, the company faces substantial doubt about its ability to continue as a going concern without additional funding. The voluntary withdrawal of the accelerated approval for the diffuse large B-cell lymphoma (DLBCL) indication marks a strategic retrenchment, though clinical development in myelofibrosis and endometrial cancer remains active with key data expected in 2026. Karyopharm’s business model centers on leveraging its first-in-class exportin 1 inhibitor platform, but competition and regulatory complexity weigh heavily. The company’s capital structure is strained by significant debt and covenant restrictions, requiring close monitoring of upcoming clinical milestones and financing developments.